Evidence map›Paper›PMID 33671112›Full record

ArticleInternational journal of molecular sciences2021

An Integrated Bioinformatics Study of a Novel Niclosamide Derivative, NSC765689, a Potential

Ntlotlang Mokgautsi, Ya-Ting Wen, Bashir Lawal, Harshita Khedkar, Maryam Rachmawati Sumitra, Alexander T H Wu, Hsu-Shan Huang

Open access · goldAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in International journal of molecular sciences, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 17 papers.

0numbers the graph read from it
0cells of the map it votes in
17citing papers in PubMed
2.1field-weighted citation impact, top 12% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

17 citing papers in PubMed, 28 citations in OpenAlex.

  1. Review
  2. Review
  3. Review
  4. Article
  5. Article
  6. Arabian journal of chemistry · 2023
    Article
  7. Article
  8. Article
  9. Article
  10. Article
  11. Article
  12. Article
  13. Article
  14. The magic bullet: Niclosamide.Frontiers in oncology · 2022
    Review
  15. Cell Biology Meets Cell Metabolism: Energy Production Is Similar in Stem Cells and in Cancer Stem Cells in Brain and Bone Marrow.The journal of histochemistry and cytochemistry : official journal of the Histochemistry Society · 2022
    Review
  16. Article
  17. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

7 authors at 3 institutions in 1 country.

Ntlotlang MokgautsiPhD Program for Cancer Molecular Biology and Drug Discovery, College of Medical Science and Technology, Taipei Medical University and Academia Sinica, Taipei 11031, Taiwan.ORCID 0000-0003-2076-9768
Ya-Ting WenDepartment of Neurosurgery, Taipei Medical University-Wan Fang Hospital, Taipei 11031, Taiwan.
Bashir LawalPhD Program for Cancer Molecular Biology and Drug Discovery, College of Medical Science and Technology, Taipei Medical University and Academia Sinica, Taipei 11031, Taiwan.ORCID 0000-0003-0676-5875
Harshita KhedkarPhD Program for Cancer Molecular Biology and Drug Discovery, College of Medical Science and Technology, Taipei Medical University and Academia Sinica, Taipei 11031, Taiwan.
Maryam Rachmawati SumitraPhD Program for Cancer Molecular Biology and Drug Discovery, College of Medical Science and Technology, Taipei Medical University and Academia Sinica, Taipei 11031, Taiwan.
Alexander T H WuTMU Research Center of Cancer Translational Medicine, Taipei Medical University, Taipei 11031, Taiwan.ORCID 0000-0002-0178-6530
Hsu-Shan HuangPhD Program for Cancer Molecular Biology and Drug Discovery, College of Medical Science and Technology, Taipei Medical University and Academia Sinica, Taipei 11031, Taiwan.
Taipei Medical University · TWTaipei Medical University Hospital · TWWan Fang Hospital · TW

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Despite management efforts with standard surgery, radiation, and chemotherapy, glioblastoma multiform (GBM) remains resistant to treatment, which leads to tumor recurrence due to glioma stem cells (GSCs) and therapy resistance. In this study, we used random computer-based prediction and target identification to assess activities of our newly synthesized niclosamide-derived compound, NSC765689, to target GBM oncogenic signaling. Using target prediction analyses, we identified

Indexed as

beta CateninBrain NeoplasmsCell DifferentiationCell ProliferationComputational BiologyGene Expression Regulation, NeoplasticGlioblastomaGlycogen Synthase Kinase 3 betaHumansHyaluronan ReceptorsMolecular Docking SimulationNeoplastic Stem CellsNiclosamideSignal TransductionSTAT3 Transcription FactorTumor Cells, Culturedbeta CateninCD44 protein, humanCTNNB1 protein, humanGlycogen Synthase Kinase 3 betaGSK3B protein, humanHyaluronan ReceptorsNiclosamideSTAT3 protein, humanSTAT3 Transcription Factordrug resistanceglioblastoma multiforme (GBM)glioma stem cell (GSC)in silico molecular dockingmiR-135bstemnesstumor microenvironment (TME)

Identifiers

PMID33671112
PMCPMC7957701
OpenAlexW3134317542

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.